NCT00854321已完成不适用
One Centre Follow-up Study on Safety and Efficacy
Kuopio University Hospital1 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2004年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 49
- 试验地点
- 1
- 主要终点
- ACR20 ACR50 ACR70 response
研究概览
简要总结
One centre follow-up study on safety and efficacy of treatment with rituximab among patients with RA during 4 year period. Basic data is collected for the national register of biologicals.
详细描述
Data is collected on regular visits in the outpatient department. In collection national register forms have been used.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •active RA without response to earlier treatment
排除标准
- •contraindications to rituximab
研究组 & 干预措施
patients with active RA
drug, follow-up
干预措施: rituximab (Drug)
patients with active RA
drug, follow-up
干预措施: rituximab, observational study amon patients with active RA (Drug)
结局指标
主要结局
ACR20 ACR50 ACR70 response
时间窗: 6 and 12 months
次要结局
- Duration of clinical response(6 and 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
终止
4 期
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic StatusLymphocytic Leukemia, ChronicNCT01271010Hoffmann-La Roche89
已完成
3 期
A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid ArthritisRheumatoid ArthritisNCT00299130Genentech, Inc.511
已完成
2 期
Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)Rheumatoid ArthritisNCT02093026Hoffmann-La Roche465
Unknown
4 期
Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus ErythematosusAutoimmune DiseasesNCT04127747Second Affiliated Hospital, School of Medicine, Zhejiang University110
已完成
不适用
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular LymphomaDiffuse Large B-Cell LymphomaNCT01340443Hoffmann-La Roche314